allogeneic anti-CD19 CAR double-negative T cells RJMty19

{
  "id": "MLC-T-ONC-009801",
  "term": "allogeneic anti-CD19 CAR double-negative T cells RJMty19",
  "field": "Oncology and biomedicine",
  "definition": "An off-the-shelf (OTS) cell preparation composed of healthy, donor-derived CD4 and CD8 double-negative T lymphocytes (DNTs) that are transduced with a lentiviral vector expressing a humanized chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR DNTs RJMty19 specifically targets and binds to tumor cells expressing CD19. This induces selective toxicity in tumor cells that express CD19. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. The DNTs contain a high proportion of stem cell-like memory T cells (Tscm).",
  "synonyms": [
    "allo-DNT cells RJMty19",
    "allogeneic anti-CD19 CAR DNT cells RJMty19",
    "allogeneic anti-CD19 CAR-engineered double negative T cells RJMty19",
    "allogeneic DNT cells RJMty19",
    "allogeneic DNTs RJMty19",
    "bi-negative T cells RJMty19",
    "CD19-CAR-DNT cells RJMty19",
    "lentiviral vector-transduced anti-CD19-CAR DNT cells RJMty19"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-anti-cd19-car-double-negative-t-cells-rjmty19/"
}